EMAIL THIS PAGE TO A FRIEND

International journal of pharmaceutics

Controlled-release triple anti-inflammatory therapy based on novel gastroretentive sponges: characterization and magnetic resonance imaging in healthy volunteers.


PMID 24928130

Abstract

The current work aimed to develop novel composite sponges of chitosan (CH)-chondroitin sulfate (CS) as a low-density gastroretentive delivery system for lornoxicam (LOR). This triple anti-inflammatory therapy-loaded matrices are expected to expand and float upon contact with gastric fluids for prolonged times. CH and CS solutions (3%, w/w) were prepared, mixed in different ratios, lyophilized, coated with magnesium stearate and compressed. The CH:CS interpolymer complex (IPC) was evaluated via FT-IR, DSC, and XRD. The compressed-sponges were evaluated for appearance, structure, porosity, pore diameter, density, wetting-time, floating characteristics, adhesion-retention, and LOR-release. The gastroretentivity of the best achieved magnetite-loaded sponges was monitored in healthy volunteers via MRI. The interaction between CH (protonated amino groups) and CS (anionic carboxylate/sulfate groups) proved IPC formation. DSC and XRD studies confirmed loss of LOR crystallinity. The sponges possessed interconnecting porous-network structures. The porosity, mean pore diameter, and bulk density of CH:CS (10:3) IPC sponges were 11.779%, 25.4 nm, and 0.670 g/mL, respectively. They showed complete wetting within seconds, gradual size-expansion within minutes and prolonged adhesion for hours. Controlled LOR-release profiles were tailored over 12h to satisfy individual patient needs. Monitoring of sponges via MRI proved their gastroretentivity for at least 5h.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

61339
D-Lactose monohydrate, BioUltra, ≥99.5% (HPLC)
C12H22O11 · H2O
61345
D-Lactose monohydrate, ≥98.0% (HPLC)
C12H22O11 · H2O
61341
D-Lactose monohydrate, tested according to Ph.Eur.
C12H22O11 · H2O
L254
D-Lactose monohydrate, ACS reagent
C12H22O11 · H2O
700312
Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size, 5 mg/mL in toluene
Fe3O4
700320
Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size, 5 mg/mL in toluene
Fe3O4
700304
Iron oxide(II,III), magnetic nanoparticles solution, 20 nm avg. part. size, 5 mg/mL in toluene
Fe3O4
725331
Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size, 5 mg/mL in H2O
Fe3O4
725358
Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size, 5 mg/mL in H2O
Fe3O4
725366
Iron oxide(II,III), magnetic nanoparticles solution, 20 nm avg. part. size, 5 mg/mL in H2O
Fe3O4
747327
Iron oxide(II,III), magnetic nanoparticles solution, 30 nm avg. part. size (TEM), amine functionalized, 1 mg/mL Fe in H2O, dispersion
Fe3O4
747424
Iron oxide(II,III), magnetic nanoparticles solution, 10 nm diameter, biotin functionalized, 1 mg/mL Fe, dispersion in H2O
Fe3O4
747254
Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size (TEM), carboxylic acid functionalized, 5 mg/mL Fe in H2O, dispersion
Fe3O4
747343
Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size (TEM), amine functionalized, 1 mg/mL Fe in H2O, dispersion
Fe3O4
747319
Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size (TEM), PEG functionalized, 1 mg/mL Fe in H2O, dispersion
Fe3O4
747300
Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size (TEM), amine functionalized, 1 mg/mL Fe in H2O, dispersion
Fe3O4
747408
Iron oxide(II,III), magnetic nanoparticles solution, 30 nm avg. part. size (TEM), PEG functionalized, dispersion, 1 mg/mL Fe in H2O
Fe3O4
747416
Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size (TEM), biotin functionalized, 1 mg/mL Fe in H2O, dispersion
Fe3O4
790508
Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size (TEM), PEG functionalized, 1 mg/mL Fe in H2O, dispersion
Fe3O4
518158
Iron(II,III) oxide, 99.99% trace metals basis
Fe3O4
637106
Iron(II,III) oxide, nanopowder, 50-100 nm particle size (SEM), 97% trace metals basis
Fe3O4
310069
Iron(II,III) oxide, powder, <5 μm, 95%
Fe3O4
529311
Iron(III) oxide, ≥99.995% trace metals basis
Fe2O3
371254
Iron(III) oxide, hydrated, catalyst grade, 30-50 mesh
HFeO2
544884
Iron(III) oxide, nanopowder, <50 nm particle size (BET)
Fe2O3
720712
Iron(III) oxide, dispersion, nanoparticles, ≤110 nm particle size, 15 wt. % in ethanol
Fe2O3
720704
Iron(III) oxide, dispersion, nanoparticles, ≤110 nm particle size, 20 wt. % in H2O
Fe2O3
PHR1024
Lactose (Monohydrate), pharmaceutical secondary standard; traceable to USP and PhEur
C12H22O11 · H2O
1356701
Lactose monohydrate, United States Pharmacopeia (USP) Reference Standard
C12H22O11 · H2O
26454
Magnesium stearate, puriss., meets analytical specification of Ph. Eur., BP, ≥90% stearic and palmitic acid basis, ≥40% stearic acid basis (GC), 4.0-5.0% Mg basis (calc on dry sub.)
C36H70MgO4